Table 2.

Baseline characteristics and treatment administered. Only patients with genotyping and PC_1/2 results are presented

	Asia		Africa
	N	Median (range) or N (%)	N	N (%) or median (range)
Age (years)	2630	21 [0.1–70]	204	4.7 [0.7–29]
< 1 year		8 [0]		11 [5]
1–4 years		185 [7]		98 [48]
5–11 years		407 [15]		82 [40]
12+ years		2030 [77]		13 [6]
Parasitemia (microliter)	2631	97,214 [455–2,409,008]	204	53,507 [2240 - 605,329]
Temperature (C)	1658	38.2 [34.1–41.5]	204	37.6 [34.7–40.8]
Hemoglobin (g/dL)	770	13.1 [2.1–19.3]	26	10.8 [6.3–14.2]
Hematocrit (%)	1542	40 [12–55]	140	31 [21–44]
Artemisinin derivative: total 3 days dose (mg/kg)
AL	0		80	9.3 [5.2–16.0]
AS	433	8.3 [1.0–49.7]	0
AS + ACT1	1638	8.3 [0.5–28.9]	83	11.8 [4.7–15]
ASAQ	0		41	13.0 [8.6–16.7]
ASMQ	81	8.0 [3.8–16.1]	0
DHAPIP	430	6.7 [3.0–17.8]	0

¹Artesunate was given in the first 3 days alone, followed by ACT